ORI Capital
Overview
Founded in 2015, ORI Capital combines deep sector expertise with proprietary AI-driven analysis to identify, support, and scale startups addressing unmet medical needs. From early clinical development…
Investment Focus
- Innovative biotech companies addressing high-mortality diseases
- Early-stage companies with a focus on diagnostics, drug delivery, or therapeutics
- Companies with a strong scientific foundation and potential for global impact
Portfolio Companies
Reach ORI Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about ORI Capital
What sectors does ORI Capital invest in?
ORI Capital invests in Healthcare, Life Sciences, Diagnostics, Biotechnology, Therapeutics and Drug Delivery, and is based in Hong Kong, Hong Kong Sar China. ORI Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does ORI Capital invest at?
ORI Capital backs companies at Seed and Early Stage, writing cheques of 1M - 10M.
Which regions does ORI Capital invest in?
ORI Capital invests across United States, Canada, Hong Kong, Japan, Australia and Europe.
Who are the partners at ORI Capital?
Team members listed for ORI Capital include Simone Song (Founder) and Nico Zheng (Vice President).
What companies has ORI Capital invested in?
ORI Capital's portfolio includes CG Oncology, BeeX, Archisen and Metaoptics.
How do I contact ORI Capital?
ORI Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
